A Study of a Single Dose of ASP3291 in Subjects With Ulcerative Colitis

NCT01320332 ↗

Phase 1 Completed 16 enrolled Telsar Pharma Inc.

RandomizedParallel-groupQuadruple-blind

Summary

The purpose of this study is to determine the pharmacokinetics (PK) and to assess safety and tolerability of a single dose of ASP3291 in subjects with ulcerative colitis.

Timeline

Start: 2010-08
Primary completion: 2011-08
Completion: 2011-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ASP3291	Unknown	—	Oral

A Study of a Single Dose of ASP3291 in Subjects With Ulcerative Colitis

Summary

Timeline

Drugs

Indications